EN DE
Watch Lisata Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lisata Therapeutics Inc. (LSTA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Lisata Therapeutics Inc. stock $1.37, price $1.03, upside +33.0%, quality 32 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LT Lisata Therapeutics Inc. logo Thin data Nov 8, 2026

Lisata Therapeutics Inc.

LSTA · US
Speculative

The stock costs 25% less than our calculation considers fair.

Fair value $1.37 · Undervalued
Revenue last quarter 90% below a year ago.
Quality 32/100
Weak Growth (revenue 3y −88.8 %/yr in USD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 6/100 · thin data
Thin data
Watch Lisata Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.80 $0.9900 Fair Value $1.37 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $0.9900 – $19.80 · fair‑value band $0.9000 – $1.71 · the $1.03 price screens below the $1.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Lisata Therapeutics in your weekly email

Every Wednesday you see whether Lisata Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Show moreShow less

Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Stock analysis

Lisata Therapeutics Inc. (LSTA) currently trades at $1.03, while our model-based Fair Value estimate is $1.37, implying the stock looks roughly 25% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: $0.9000 (bear) to $1.71 (bull), the price of $1.03 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Lisata Therapeutics Inc. reported revenue of $170K in FY2025 versus $0 in FY2021. Reported net income was −$16.6M in FY2025.

Key figures

Market cap $11.1M Micro · EPS (TTM) $−1.64 · Return on equity −102% · Return on assets (EBIT) −64.5% (5-year average) · Operating margin −16,426% · Revenue (TTM) $100K · Revenue growth (YoY) −90.0% · Free cash flow −$16.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 33%, LSTA screens cheaper than that median.

Fair Value models

Bear $0.9000 Fair Value $1.37 Bull $1.71
Price $1.03 · Upside +33.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.9000 $1.37 $1.71 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.9000 $1.37 $1.71 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 8
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 73
Does it invest with discipline instead of growing at any price?
Low Volatility 30
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 36
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−83.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−88.8%
Revenue growth 35 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.1% (1990) → −10,711.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LSTA, get fair value alerts →

Compare Lisata Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside +33.0% · Top 25%
Profitability
Return on assets −93.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −90.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.75× · Cheapest 25%
PEG 118.40× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)77 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs LSTA
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs LSTA
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs LSTA
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs LSTA
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs LSTA
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs LSTA
argenx SE ARGX $927.21 $908.40 −2% vs LSTA
CSL Limited CSL A$200.77 A$183.04 −9% vs LSTA
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs LSTA
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs LSTA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lisata Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lisata Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/LSTA

Frequently asked questions

Is Lisata Therapeutics Inc. (LSTA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.37 versus a price of $1.03, about +33% upside (undervalued).
What is the fair value of LSTA?
Our model-based fair value for Lisata Therapeutics Inc. is $1.37 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.03.
What is the quality score of LSTA?
Lisata Therapeutics Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lisata Therapeutics Inc. (LSTA)?
Our model-based price target is the fair value of $1.37 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.9000, optimistic scenario $1.71. It is a calculation from audited fundamentals, not an analyst target.
What is the Lisata Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $1.37, about +33% upside versus a price of $1.03 (undervalued). Cautious scenario $0.9000, optimistic scenario $1.71. The calculation is refreshed regularly with new filings.
What is the revenue of Lisata Therapeutics Inc. (LSTA)?
Lisata Therapeutics Inc. reported trailing-twelve-month revenue of about $100K (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Lisata Therapeutics Inc. (LSTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lisata Therapeutics Inc. it is $1.37 per share (as of Nov 8, 2026), against a price of $1.03. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Lisata Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, LSTA trades below its calculated fair value: price $1.03, fair value $1.37, a gap of about +33% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LSTA?
No. The price is what the market pays today ($1.03); the fair value is what the company's own numbers justify ($1.37). For Lisata Therapeutics Inc. the two are $0.3400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lisata Therapeutics Inc. worth?
The market values Lisata Therapeutics Inc. at about $11.1M (market capitalisation, as of Nov 8, 2026). Per share that is $1.03; our models calculate a fair value of $1.37 per share.
What do the bullish and bearish scenarios say about LSTA?
Our models span a range for Lisata Therapeutics Inc.: cautious scenario $0.9000, base $1.37, optimistic $1.71 per share (as of Nov 8, 2026, price $1.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of LSTA?
The PEG ratio of Lisata Therapeutics Inc. is 118.40 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Lisata Therapeutics Inc. (LSTA)?
Balance-sheet figures for Lisata Therapeutics Inc. (as of Nov 8, 2026): return on equity −101.7%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is LSTA from its 52-week high?
Lisata Therapeutics Inc. trades at $1.03, about 80% below its 52-week high of $5.04 and 4% above the low of $0.9900 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.37 is for.
Which stocks are comparable to Lisata Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lisata Therapeutics Inc. stock attractive at the current price?
The data as of Nov 8, 2026: price $1.03, calculated fair value $1.37 (+33%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LSTA calculated?
We run Lisata Therapeutics Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.37 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lisata Therapeutics Inc. currently trades 25% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lisata Therapeutics Inc. (LSTA)?
The closing price on Nov 6, 2026 was $1.03. Our model-based fair value is $1.37, about +33% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lisata Therapeutics Inc. right now?
The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.9000 to $1.71) leaves room in how you read the outcome.

Key figures of Lisata Therapeutics Inc.

How large is the market capitalisation of Lisata Therapeutics Inc. (LSTA)?
The market capitalisation of Lisata Therapeutics Inc. is $11.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Lisata Therapeutics Inc. (LSTA)?
Earnings per share at Lisata Therapeutics Inc. are $−1.64. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lisata Therapeutics Inc. (LSTA)?
The return on equity (ROE) of Lisata Therapeutics Inc. is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lisata Therapeutics Inc. (LSTA)?
On an EBIT basis the return on assets of Lisata Therapeutics Inc. is −64.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lisata Therapeutics Inc. (LSTA)?
The operating margin of Lisata Therapeutics Inc. is −16,426% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lisata Therapeutics Inc. (LSTA)?
Revenue at Lisata Therapeutics Inc. is growing −90.0% versus a year earlier (3y avg −88.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lisata Therapeutics Inc. (LSTA) generate?
The free cash flow of Lisata Therapeutics Inc. is −$16.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lisata Therapeutics Inc. (LSTA) hold?
Lisata Therapeutics Inc. holds more cash than debt, $16.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lisata Therapeutics Inc. in the live analysis

One click puts Lisata Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.